Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$191.49
+0.6%
$174.03
$111.09
$199.99
$11.71B0.41522,543 shs1.55 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$40.62
-0.6%
$45.11
$19.44
$53.27
$2.65B2.18537,031 shs840,550 shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.12
-1.8%
$29.26
$23.15
$91.99
$10.16B1.838.18 million shs6.60 million shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$48.02
-0.7%
$48.02
$37.63
$51.88
$10.68B0.641.64 million shs1.29 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+9.75%+8.50%+26.60%+54.90%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
0.00%-5.45%-10.15%+35.08%+0.77%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-5.36%-23.80%+7.71%-67.97%
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.00%-3.77%-1.11%+14.69%+11.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.4178 of 5 stars
4.52.00.00.03.31.70.6
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.3176 of 5 stars
4.63.00.00.02.22.50.0
Moderna, Inc. stock logo
MRNA
Moderna
4.4694 of 5 stars
4.01.00.04.62.82.51.3
QIAGEN N.V. stock logo
QGEN
QIAGEN
3.5491 of 5 stars
1.12.01.74.52.71.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$239.8025.23% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.10
Buy$59.1145.52% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$43.5966.88% Upside
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.27
Hold$49.693.47% Upside

Current Analyst Ratings Breakdown

Latest KYMR, QGEN, MRNA, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$289.00 ➝ $295.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$243.00 ➝ $290.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$210.00 ➝ $230.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$306.00 ➝ $307.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$212.00 ➝ $220.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $203.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$212.00 ➝ $254.00
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M29.75N/AN/A($1.88) per share-101.86
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M56.20N/AN/A$12.90 per share3.15
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.14N/AN/A$28.33 per share0.92
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.40$3.20 per share14.99$16.05 per share2.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$5.16N/A797.88N/A-54.94%N/A-24.31%N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/11/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%N/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$1.6928.3719.522.4518.30%14.77%8.87%N/A

Latest KYMR, QGEN, MRNA, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.84N/AN/AN/A$17.37 millionN/A
8/7/2025Q2 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million
8/5/2025Q2 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.60$0.60N/A$0.44$523.97 million$533.54 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%N/A14.79%N/A

Latest KYMR, QGEN, MRNA, and ASND Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%7/2/20257/3/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.02
0.69
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.49
8.49
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.25
1.61
1.35

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
QIAGEN N.V. stock logo
QGEN
QIAGEN
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.15 million36.69 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.69 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable

Recent News About These Companies

William Blair Has Optimistic Outlook of Qiagen Q1 Earnings
Qiagen (NYSE:QGEN) Issues FY 2025 Earnings Guidance
Qiagen (NYSE:QGEN) Issues Q3 2025 Earnings Guidance
Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript
A Look at Qiagen's Upcoming Earnings Report
Qiagen (QGEN) Matches Q2 Earnings Estimates
Wall Street Zen Upgrades Qiagen (NYSE:QGEN) to Strong-Buy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$191.49 +1.14 (+0.60%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$190.99 -0.50 (-0.26%)
As of 08/8/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$40.62 -0.23 (-0.56%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$40.62 +0.01 (+0.01%)
As of 08/8/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.12 -0.49 (-1.84%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$26.16 +0.04 (+0.15%)
As of 08/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$48.02 -0.34 (-0.70%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$48.00 -0.02 (-0.03%)
As of 08/8/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.